PCI Biotech is developing a new treatment solution for extrahepatic bile duct cancer. Cancerous form is a relatively rare type of cancer with no approved treatment options. In Europe and the USA, the company conducted a clinical study of a new treatment for bile duct cancer, documenting the safety and efficacy of marketing authorization.
Building on the encouraging results of the phase 1 study, PCI Biotech has launched a clinical trial called “RELEASE”.
beat the competition
The decision to discontinue RELEASE is based on the results of other clinical trials provided by it American Society of Clinical Gastrointestinal Cancer Symposium On day 20-22. January.
The TOPAZ-1 study showed that a combination of immunosuppressive control point combination with gemcitabine and cisplatin provided a significant survival benefit for patients with advanced cholangiocarcinoma, compared with the combination of placebo, gemcitabin and cisplatin in the RELEASE study.
The company anticipates that these findings will rapidly change the standard of first-line treatment for patients with inoperable cholangiocarcinoma or distal cholangiocarcinoma, the patient group the RELEASE study is aimed at.
Such a change in standard treatment would make the RELEASE study difficult to complete, and potentially insufficient for its approval.
– Stopping the release was a difficult decision, but it is necessary to make such decisions when the competitive landscape changes in this way. The RELEASE study required tremendous effort, not least from participating patients and our investors, says CEO Per Walday.
On Monday, PCI Biotech on the Oslo Stock Exchange fell 10.36 percent.